title: Stereotactic body radiotherapy for oligometastatic disease.
abstract: Stereotactic body radiotherapy (SBRT) is now an established therapy in stage I lung cancer with comparable local control rates to surgical resection. Owing to the conformity of treatment dose delivery and with appropriate fractionation considerations, minimal side-effects to surrounding normal tissues are observed in most patients. SBRT is now being used in the treatment of oligometastatic disease, alone or alongside systemic therapy. At present there is a paucity of evidence available showing a clinical benefit, but several international studies are being set-up or have started recruitment. This overview considers the clinical entity of an oligometastatic state, discusses the role of SBRT in the management of oligometastatic disease and discusses potential novel therapy combinations with SBRT.
authors.affiliation: Centre for Cancer Research and Cell Biology, Queen's University of Belfast, Belfast, UK.
authors.forename: G G
authors.initials: GG
authors.lastname: Hanna
authors.affiliation: Department of Oncology, Guys and St Thomas' Hospital, Division of Imaging Sciences, King's College London, London, UK. Electronic address: david.landau@kcl.ac.uk.
authors.forename: D
authors.initials: D
authors.lastname: Landau
mesh_terms: D019583:Dose Fractionation, Radiation; D006801:Humans; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D009369:Neoplasms / Q000473:pathology / Q000601:surgery*; D016634:Radiosurgery / Q000379:methods*
keywords: Oligometastases; SABR; SBRT; stereotactic